Skip to content

ADAGIO MEDICAL HOLDINGS, INC.: 10-Q filed 2024-08-26

What ADAGIO MEDICAL HOLDINGS, INC. reported in its quarterly report filed 2024-08-26 (fiscal Q2 2024): 12 published measures, 23 facts as tagged in accession 0001410578-24-001560.

This filing

Form
10-Q (quarterly report)
Filed
2024-08-26
Fiscal period
fiscal Q2 2024
Accession
0001410578-24-001560 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ADAGIO MEDICAL HOLDINGS, INC. filings.

Reported measures

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-06-305,000USD
At 2023-12-315,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-06-30-5,000USD
At 2024-03-31-5,000USD
At 2023-12-31-5,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-713,794USD91
2024-01-01 to 2024-06-30-2,134,199USD182
2024-01-01 to 2024-03-31-1,420,405USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-06-300USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-06-30-2,139,199USD
At 2023-12-31-5,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-04-01 to 2024-06-301shares91
2024-01-01 to 2024-06-301shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-04-01 to 2024-06-301shares91
2024-01-01 to 2024-06-301shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-713,794USD/shares91
2024-01-01 to 2024-06-30-2,134,199USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-04-01 to 2024-06-30-713,794USD/shares91
2024-01-01 to 2024-06-30-2,134,199USD/shares182

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-06-300USD
At 2023-12-310USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-06-302,134,199USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-01-01 to 2024-06-30-2,134,199USD182

Inspect the source

Entity
ADAGIO MEDICAL HOLDINGS, INC. / CIK 0002006986
Captured
2026-09-21T17:42:52.193Z
SEC response SHA-256
eb0741ca13c5d507cf2d9238a7947632ef8ec98c555ede03b5fc8021f83b1483

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0002006986.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))